GlassScriptPhysician profile
Michael W Wooley
NPI 1396749743
$1,975.52
in general payments reported to CMS, 2019-2025
15 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $13.88 · 2021: $252 · 2022: $365 · 2023: $253 · 2024: $413 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $547.07 | 2019-2024 | Breztri, Tezspire |
| Glaxosmithkline, LLC. | $438.41 | 2019-2023 | Arexvy |
| Jazz Pharmaceuticals INC. | $157.07 | 2024-2025 | |
| Inspire Medical Systems, INC. | $147.68 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $143.61 | 2019-2021 | |
| Penumbra, INC. | $142.50 | 2025 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.95 | 2019-2025 | Ofev |
| Harmony Biosciences LLC | $124.99 | 2021 | |
| Abbvie INC. | $35.03 | 2022-2024 | |
| Resmed Corp | $24.73 | 2023 | |
| Grifols USA, LLC | $23.10 | 2019 | |
| Axsome Therapeutics, INC. | $18.85 | 2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $17.85 | 2025 | Lumryz |
| Shire North American Group INC | $15.59 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.